Nanobiotix SA
PAR:NANO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.296
7.54
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Nanobiotix SA
Depreciation & Amortization
Nanobiotix SA
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Nanobiotix SA
PAR:NANO
|
Depreciation & Amortization
-€1.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-30%
|
||
Valneva SE
PAR:VLA
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
G
|
Genfit SA
PAR:GNFT
|
Depreciation & Amortization
-€1.5m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-20%
|
|
Inventiva SA
PAR:IVA
|
Depreciation & Amortization
-€3.2m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
||
Eurobio Scientific SA
PAR:ALERS
|
Depreciation & Amortization
-€8.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-18%
|
||
OSE Immunotherapeutics SA
PAR:OSE
|
Depreciation & Amortization
-€3.4m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
N/A
|
Nanobiotix SA
Glance View
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
See Also
What is Nanobiotix SA's Depreciation & Amortization?
Depreciation & Amortization
-1.9m
EUR
Based on the financial report for Jun 30, 2024, Nanobiotix SA's Depreciation & Amortization amounts to -1.9m EUR.
What is Nanobiotix SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-30%
Over the last year, the Depreciation & Amortization growth was -14%. The average annual Depreciation & Amortization growth rates for Nanobiotix SA have been 3% over the past three years , -10% over the past five years , and -30% over the past ten years .